维普期刊资源整合服务平台（V6.5）

25篇 您的检索式：作者名="AMARAVADI L"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	A rapid and efficient non-radioactive method for screening recombinant DNA libraries 显示文摘	Amaravadi L King M W	1994	Biotechniques1994，16，1：	1
2	Rec- ommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products 显示文摘	SHANKAR G DEVANARAYAN V AMARAVADI L	2008	J Pharma Biomed Anal2008，48，5：	1
3	The MAPK pathway in melanoma显示文摘	Fecher L A Amaravadi R K Flaherty	2008	Curr Opin Oncol2008，20，2：	1
4	A rapid and efficient non-radioactive method for screening recombinant DNA library 显示文摘	Amaravadi L King MW	1994	Bio Technique1994，，1：	1
5	Immunogenicity of bio-logically- derived therapeutics : assessment and interpretation ofnonclinical safety studies显示文摘	Ponce R Abad L Amaravadi L	2009	Regul Toxicol Pharmacol2009，54，2：	1
6	Safety, tolerabili- ty, pharmacokinetics, and pharmacodynamics of anti - TWEAK monoclonal antibody in patients with rheumatoid arthritis 显示文摘	Wisniacki N Amaravadi L Galluppi GR	2013	Clin Ther2013，35，8：	1
7	Immunogenieity of biologically-derived therapeutics: assessment andinterpretation of nonclinical safety studies 显示文摘	Ponce R Abad L Amaravadi L	2009	Regul Toxicol Pharmacol2009，54，2：	1
8	New FDA draft guidance on immunogenicity显示文摘	PARENKY A MYLER H AMARAVADI L	2014	AAPS J2014，16，3：	1
9	A rapid and efficient nonradioactive method for screening recombinant DNA libraries显示文摘	King M W	1994	Biotechniques1994，16，1：	1
10	A white paper-Consensus and recommendations of a global harmo-nization team on assessing the impact of immunogenicity on phar-macokinetic measurements显示文摘	SAILSTAD JM AMARAVADI L CLEMENTS-EGAN A	2014	AAPS J2014，16，3：	1
11	Mice deficient in fractalkine are less susceptible to cerebral ischemia-reperfusion injury 显示文摘	Soriano S G Amaravadi L S Wang Y F	2002	J Neuroimmunol2002，125，12：	1
12	Characterization and expression of the Xenopus c-Myb homolog显示文摘	Amaravadi L King M W	1994	Oncogene1994，9，3：	1
13	Recommendations for the validation of immunoassays used for de-tection of host antibodies against biotechnology products显示文摘	SHANKAR G DEVANARAYAN V AMARAVADI L	2008	JPharm Biomed Anal2008，48，5：	1
14	Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products 显示文摘	SHANKAR G DEVANARAYAN V AMARAVADI L	2008	J Pharm Biomed Anal2008，48，5：	1
15	Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies 显示文摘	Ponce R Abad L Amaravadi L	2009	Regul Toxicol Pharmacol2009，54，2：	1
16	The MAPK pathway in melanoma显示文摘	FECHER L A AMARAVADI R K FLAHERTY K T	2008	Curr Opin Oncol2008，20，2：	1
17	The MAPK pathway in melanoma显示文摘	Fecher L A Amaravadi R K Flaherty K T	2008	Curr Opin Oncol2008，20，：	1
18	Phase trial of temozolomide and sorafenib in advanced melanoma patients with or without brain metastases 显示文摘	AMARAVADI R K SCHUCHTER L M MCDERMOTT D F	2009	Clin Cancer Res2009，15，24：	1
19	The MAPK pathway in melanoma显示文摘	FECHER L A AMARAVADI R K FLAHERTY K T	2008	Current Opinion in Oncology2008，20，2：	1
20	New FDA draft guidance on immunogenicity 显示文摘	Parenky A Myler H Amaravadi L	2014	AAPS J2014，16，3：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示